eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2022
vol. 39
 
Share:
Share:
abstract:
Original paper

The efficacy of high-flow oxygen versus conventional oxygen for asthma control: a meta-analysis of randomized controlled studies

Haoyue Deng
1, 2
,
Yongpeng He
3
,
Xiaoqin Fu
3
,
Zhiqiang Mei
2
,
Yi Li
4

1.
Department of Gastroenterology Suining First People's Hospital, Suining, Sichuan, China
2.
The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan, China
3.
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China
4.
Department of Thoracic Surgery Suining Central Hospital, Suining, Sichuan, China
Adv Dermatol Allergol 2022; XXXIX (6): 1077-1082
Online publish date: 2022/09/07
View full text Get citation
 
Introduction
The efficacy of high-flow oxygen versus conventional oxygen therapy for asthma control remains controversial.

Aim
This meta-analysis aims to explore the influence of high-flow oxygen versus conventional oxygen therapy on asthma control.

Material and methods
We have searched PubMed, Embase, Web of Science, EBSCO, and Cochrane library databases, and included randomized controlled trials (RCTs) assessing the efficacy of high-flow oxygen versus conventional oxygen therapy for asthma control.

Results
Four RCTs are included in this meta-analysis. Overall, compared with conventional oxygen therapy for asthma, high-flow oxygen is associated with a significantly lower dyspnoea score (standard mean difference (SMD) = –0.63; 95% confidence interval (CI): –1.08 to –0.17; p = 0.008), but reveals no remarkable influence on PaCO2 (SMD = 0.28; 95% CI: –0.22 to 0.77; p = 0.28), PaO2 (SMD = 0.44; 95% CI: –1.34 to 2.22; p = 0.63), intubation rate (OR = 1.09; 95% CI: 0.15 to 8.21; p = 0.93) or hospital length of stay (SMD = –0.07; 95% CI: –0.41 to 0.27; p = 0.67).

Conclusions
High-flow oxygen may benefit to reduce/may be more beneficial in reducing the dyspnoea score than conventional oxygen therapy for asthma, but shows no improvement in PaCO2, PaO2, intubation or hospital length of stay.

keywords:

high-flow oxygen, conventional oxygen, asthma, randomized controlled trials

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.